Want to see HK:2591 full AI Analyst Report?
2591 Stock Chart & Stats
HK$7.10
--
Market closed
HK$7.10
--
Day’s Range― - ―
52-Week RangeHK$3.15 - HK$48.36
Previous CloseN/A
VolumeN/A
Average Volume (3M)8.53M
Market Cap
HK$1.61B
Enterprise ValueHK$2.23B
Total Cash (Recent Filing)HK$1.02B
Total Debt (Recent Filing)HK$151.19M
Price to Earnings (P/E)―
Beta1.04
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding420,285,370
10 Day Avg. Volume4,959,820
30 Day Avg. Volume8,525,279
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)11.34
Price to Sales (P/S)93.25
P/FCF Ratio-37.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Inflection And Gross MarginThe sharp 2025 revenue inflection shows that the company has begun generating commercial sales, while the high reported gross margin indicates attractive economics on those sales. If revenue continues scaling, this gross-profit base could provide operating leverage and support eventual profitability.
Equity Funding And Moderate LeverageMeaningful equity funding and moderate leverage provide a comparatively supportive financial base for an R&D-heavy biotechnology company. This structure gives management greater flexibility to fund development and commercialization, although that flexibility remains dependent on controlling losses and cash consumption.
Improving Cash-burn TrendThe reduction in cash burn from 2023 suggests that operating performance has improved as revenue emerged, which is a constructive trend for a development-stage business. Continued improvement could extend funding capacity and reduce financing pressure as commercialization progresses, even though cash generation is not yet positive.
Bears Say
Persistent Operating LossesVery large operating and net losses relative to current revenue show that the cost base remains far ahead of commercialization. This limits the company’s ability to fund growth internally, makes profitability dependent on substantial revenue scaling or expense reductions, and keeps execution risk elevated over the coming quarters.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flow means the business is not yet self-funding despite the 2025 revenue ramp. Persistent cash consumption can require continued balance-sheet support or additional financing, reducing financial flexibility and increasing the importance of achieving scale and narrowing losses.
Rising Debt And Negative ReturnsThe increase in total debt alongside deeply negative returns indicates that additional financing has not yet translated into adequate earnings power. If losses persist, leverage may continue rising to support operations, potentially increasing funding requirements and limiting capital-allocation flexibility even from a moderate starting debt level.
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H News
2591 FAQ
What was Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s price range in the past 12 months?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H lowest stock price was HK$3.15 and its highest was HK$48.36 in the past 12 months.
What is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s market cap?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s market cap is HK$1.61B.
When is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s earnings last quarter?
Currently, no data Available
Is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H overvalued?
According to Wall Street analysts Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s price is currently Overvalued.
Does Guangzhou Innogen Pharmaceutical Group Co Ltd Class H pay dividends?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H does not currently pay dividends.
What is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s EPS estimate?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guangzhou Innogen Pharmaceutical Group Co Ltd Class H have?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H has 420,285,370 shares outstanding.
What happened to Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Guangzhou Innogen Pharmaceutical Group Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.48%
12-Months-Change
Fundamentals
Return on Equity
-32.98%
Trailing 12-Months
Asset Growth
46.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co Ltd operates as a China-based investment holding firm with a core mission to research, develop, and bring to market medicinal products. The company specializes in producing innovative, human-compatible, and extended-duration GLP-1 receptor agonists, specifically targeting the treatment of diabetes and other metabolic conditions.
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H (2591) Earnings & Revenues
Technical Analysis
Alphamab Oncology
―
RemeGen Co. Ltd. Class H
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Ascentage Pharma Group International
―